Cell and gene therapies are revolutionizing the healthcare market landscape. The fast growth of this sector (CAGR: 21,9%) has not allowed for manufacturing technologies to keep up, and most processes still rely on technologies inherited from the vaccines or mAbs industries. Producing advanced therapies using current traditional technologies face several limitations including scalability, limited robustness of manual operations, or the need for flexibility to accommodate various products with ease and manufacturing at reasonable costs. This poses critical issues as products approach late clinical stages and commercialization, leading today to a growing capacity gap. The key to success is to deliver these products in high quantity in a small footprint without compromising on quality, which is possible through technology innovation and dissemination.
By switching from conventional to intensification and automation principles, the next generation of gene therapy manufacturing technologies will be able to meet the capacity demand of commercial viral vector manufacturing. To ensure a successful adoption and workforce empowerment, it is essential for these new technologies to guarantee a fast learning curve via ease of use and simplicity of process transfer and scale-up. Solution providers are responsible to share the appropriate trainings and know-how to rapidly upskill the manufacturing workforce of tomorrow and unlock the availability of gene therapies.
In this webinar you will learn more about:
1. The challenges encountered by innovators, researchers & manufacturers when looking at scaling-up their CGT processes to achieve commercial manufacturing.
2. The technology landscape reclaimed from the mAbs and vaccines industries and how they fail at meeting the requirements of CGT manufacturing and capacity demands.
3. How technology innovation can support advancement of the clinical pipeline and contribute to upskilling the manufacturing workforce.